Faruqi & Faruqi Reminds Cerevel Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - CERE

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC, and Pfizer, Inc. for alleged violations of federal securities laws, particularly concerning misleading statements and undisclosed material facts related to Cerevel's stock offerings and acquisition processes [6][7]. Group 1: Legal Actions and Allegations - The class action targets investors who sold or held shares of Cerevel between October 11, 2023, and August 1, 2024, claiming damages due to violations of the Securities Exchange Act [1]. - The lawsuit alleges that Bain Capital acquired shares during a secondary offering while possessing nonpublic information about AbbVie's interest in acquiring Cerevel, leading to significant profits for Bain when the acquisition was later disclosed at $45 per share [6][7]. - The complaint also claims that Cerevel's proxy statement misled investors regarding the sales process and conflicts of interest, suggesting that Bain and Pfizer orchestrated the offering to maximize profits at the expense of public shareholders [6][7]. Group 2: Investor Information and Actions - Faruqi & Faruqi, LLP is investigating claims against Cerevel and reminds investors of the June 3, 2025, deadline to seek lead plaintiff status in the class action [4]. - Investors are encouraged to contact Faruqi & Faruqi for discussions regarding their legal rights and potential claims related to the lawsuit [1][9]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995, indicating its experience in handling such cases [5].